TrialFrontiers in immunology2023

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.

Jie Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.